Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| I9X-MC-MTAB | Other Identifier | Eli Lilly and Company |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study uses imaging to evaluate how LY3372689 binds to a protein in the brain. This study will be conducted in healthy participants and will last up to approximately 25 days after enrollment. Screening must be completed within 28 days prior to enrollment.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| LY3372689 + [18F]LSN3316612 | Experimental | LY3372689 administered orally followed by [18F]LSN3316612 PET tracer administered intravenously (IV) approximately 2 - 72 hours later. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| LY3372689 | Drug | Administered orally. |
| |
| [18F]LSN3316612 |
| Measure | Description | Time Frame |
|---|---|---|
| Percent O-GlcNAcase (OGA) Enzyme Occupancy (EO) | Percent OGA EO | Predose Scan (Days -14 to -1) |
| Percent OGA EO | Percent OGA EO | Postdose Scan 1 (Days 1 - 4) |
| Percent OGA EO | Percent OGA EO | Postdose Scan 2 (Days 2 - 4) |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) | Eli Lilly and Company | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Invicro, Institute for Neurodegenerative Disorders | New Haven | Connecticut | 06510 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Diagnostic Test |
Administered IV. |
|
|